Fidelity Ventures

Fidelity Ventures, originally established in 1969, holds a significant place in the history of venture capital as the precursor to F-Prime Capital. For over five decades, this Boston-based firm has evolved from being the venture arm of Fidelity Investments to an independent global venture capital entity, having officially spun out in 2015. F-Prime Capital maintains a sharp focus on two primary sectors: healthcare and technology, seeking to back innovative companies that are poised to disrupt their respective markets.

The firm's investment philosophy is characterized by its patient and long-term approach, providing capital and strategic support to entrepreneurs from the earliest stages. F-Prime Capital typically engages with companies at the seed, Series A, and Series B stages, often taking a lead or co-lead position in funding rounds. Their commitment extends beyond just capital, aiming to help portfolio companies navigate market challenges and accelerate product development.

F-Prime Capital is known for its substantial initial investments, generally committing between $5 million and $15 million in its first checks to promising startups. This significant capital infusion is designed to provide a robust foundation for early-stage growth. Over its long tenure, the firm has cultivated a diverse portfolio of successful ventures across both its healthcare and technology verticals. Notable investments include companies like Toast in the fintech space and Denali Therapeutics in biotechnology, demonstrating their ability to identify and nurture high-growth potential.